Search
Congratulations to six researchers from The Kids Research Institute Australia, who will use valuable support from the Raine Medical Research Foundation’s 2024 grant round to undertake projects focused on improving the health and wellbeing of babies, children and young people.
Two Perth clinician-scientists have been recognised as national leaders in infectious disease research after being elected as Fellows of the esteemed Australian Academy of Health and Medical Sciences.
The Wesfarmers Centre of Vaccines and Infectious Diseases (WCVID) awarded three successful recipients with Catalyst research grants, with each researcher receiving $80,000 towards their chosen project.
One out of every 10 children with a bloodstream infection are infected with a multi-drug resistant organism in the nation’s first-ever surveillance study investigating the prevalence of paediatric antimicrobial resistance (AMR).
The National Health and Medical Research Council (NHMRC) has launched their sixth edition of Staying healthy: Preventing infectious diseases in early childhood education and care services in a bid to tackle the transmission of germs amongst young kids.
Vital research promoting sun smart choices and skin cancer prevention for young Aboriginal people is now underway at The Kids Research Institute Australia thanks to a $100,000 Perpetual 2024 IMPACT Philanthropy grant.
A team led by Dr Joseph Kado from the Wesfarmers Centre of Vaccines and Infectious Diseases, based at The Kids Research Institute Australia, and The University of Western Australia (UWA) has been awarded $5 million by the Federal Government in a major push to prevent rheumatic heart disease across the Pacific.
Christopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases
The meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) is licensed for use in children aged 10 years or older for protection against invasive serogroup B meningococcal disease. Because young children are at increased risk of invasive meningococcal disease, MenB-FHbp clinical data in this population are needed.
To assess the pharmacokinetics, safety, and tolerability of two high-dose, short-course primaquine (PQ) regimens compared with standard care in children with Plasmodium vivax infections.